Lack of miRNA misregulation at early pathological stages in *Drosophila* neurodegenerative disease models

**Anita Reinhardt**¹, Sébastien Feuillette²,³, Marlène Cassar⁴, Céline Callens⁴, Hélène Thomassin⁵, Serge Birman⁴, Magalie Lecourtis²,³, Christophe Antoniewski⁵ and Hervé Tricoire¹*  

¹ Laboratoire de Génétique du Stress et du Vieillissement, Unité de Biologie Fonctionnelle et Adaptive, CNRS EAC 4413, Université Paris Diderot, Sorbonne Paris Cité, Paris, France  
² INSERM, U1079, Rouen, France  
³ Institute for Research and Innovation in Biomedicine, University of Rouen, Rouen, France  
⁴ Genetics and Physiopathology of Neurotransmission, Neurobiology Unit, CNRS, ESPCI ParisTech, Paris, France  
⁵ Génétique et Epigénétique de la Drosophile, UMR 7822 Biologie du Développement, UPMC-CNRS 9, Paris, France  

*Correspondence:* Hervé Tricoire, Laboratoire de Génétique du Stress et du Vieillissement, Unité de Biologie Fonctionnelle et Adaptive, CNRS EAC 4413, Université Paris Diderot, Sorbonne Paris Cité, Paris, France  
e-mail: herve.tricoire@univ-paris-diderot.fr

Edited by: Peng Jin, Emory University School of Medicine, USA  
Reviewed by: Rory Johnson, Centre for Genomic Regulation, Spain  
Michael Palladino, University of Pittsburgh School of Medicine, USA  
Daniela Zanescu, University of Arizona, USA

INTRODUCTION

Late onset human neurodegenerative diseases represent a major public health concern as the population in many countries ages. Both frequent diseases such as Alzheimer disease (AD, 14% incidence for 80–84 year-old Europeans) or Parkinson disease (PD, 1.4% prevalence for >55 years old) share, with other low-incidence neurodegenerative pathologies such as spinocerebellar ataxias (SCAs, 0.01% prevalence) and frontotemporal lobar degeneration (FTLD, 0.02% prevalence), a lack of efficient treatment in spite of important research efforts. Besides significant progress, studies with animal models have revealed unexpected complexities in the degenerative process, emphasizing a need to better understand the underlying pathological mechanisms. Recently, microRNAs (miRNAs), a class of small regulatory non-coding RNAs, have been implicated in some neurodegenerative diseases. The current data supporting a role of miRNAs in PD, tauopathies, dominant ataxias, and FTLD will first be discussed to emphasize the different levels of the pathological processes which may be affected by miRNAs. To investigate a potential involvement of miRNA dysregulation in the early stages of these neurodegenerative diseases we have used *Drosophila* models for seven diseases (PD, 3 FTLD, 3 dominant ataxias) that recapitulate many features of the human diseases. We performed deep sequencing of head small RNAs after 3 days of pathological protein expression in the fly head neurons. We found no evidence for a statistically significant difference in miRNA expression in this early stage of the pathological process. In addition, we could not identify small non-coding CAG repeat RNAs (sCAG) in polyQ disease models. Thus our data suggest that transcriptional deregulation of miRNAs or sCAG is unlikely to play a significant role in the initial stages of neurodegenerative diseases.

Keywords: miRNA, neurodegenerative diseases, ataxia, frontotemporal lobar degeneration, Parkinson disease, polyQ diseases, deep sequencing

Late onset neurodegenerative diseases represent a major public health concern as the population in many countries ages. Both frequent diseases such as Alzheimer disease (AD, 14% incidence for 80–84 year-old Europeans) or Parkinson disease (PD, 1.4% prevalence for >55 years old) share, with other low-incidence neurodegenerative pathologies such as spinocerebellar ataxias (SCAs, 0.01% prevalence) and frontotemporal lobar degeneration (FTLD, 0.02% prevalence). In spite of the large clinical heterogeneity of these diseases, age is the most prominent risk factor for all of them (Yankner et al., 2008; Brookmeyer et al., 2011). Consequently, since the mean age of world population is steadily increasing, they are becoming a major health concern and economic burden in both developed and developing countries.

Although, for some of the diseases, sporadic cases are the most frequent, investigations conducted during the last decades have identified key genes associated with familial forms. This paved the way to myriads of studies using either cells or animal models to understand the physiological basis of these diseases, with significant success. A common hallmark of several of these aging-associated neurodegenerative disorders that emerged from these early studies, is the existence of fibrillar aggregates of aggregation-prone proteins that may trap other cellular compounds (Jucker and Walker, 2011). Impairment of protein quality control homeostasis during aging or in response to environmental or endogenous stresses (notably oxidative stress) may thus contribute to neuronal dysfunction. However, whether such aggregates or intermediate forms are toxic or protective is still a matter of debate. Additionally, animal models have revealed unexpected complexities in the degenerative process that cannot be reduced to a single pathological mechanism. Thus, much remains to be learned of the mechanisms leading to specific neuronal death in late onset diseases.
MicroRNAs (miRNAs) have been recently identified as potential important players in neurodegenerative diseases. miRNAs are small non-coding RNAs, present in many multicellular organisms including humans, that post-transcriptionally regulate the expression of their target genes by inhibition of mRNA translation or mRNA degradation (Krol et al., 2010). Since miRNAs can simultaneously and rapidly target hundreds of genes, it is not surprising that they have been shown to play an important role in many developmental processes and in cellular homeostasis (Kloosterman and Plasterk, 2006; Bushati and Cohen, 2007). Due to these crucial functions, their activity has to be tightly regulated at many levels.

Besides minor alternative pathways, the canonical biogenesis pathway of miRNAs involves (1) the synthesis of a long primary transcript (pri-miRNA), (2) the cleavage of the pri-miRNA into a 70–100 nt precursor (pre-miRNA) inside a nuclear multiprotein complex called the Microprocessor containing the RNase III Drosha, (3) the transport of the pre-miRNA into the cytoplasm where it is cleaved by another RNase III enzyme, Dicer, into a 21–22 nt long duplex, and (4) the association of one the strands of the duplex (the active miRNA) with an Argonaute (Ago) protein within the RISC complex, where it plays its repressive role. Due to this complex process, the level of expression of a miRNA may be regulated at several levels. One standard way is through transcriptional regulation of the pri-miRNA synthesis that will impact the level of miRNA. This accounts for a large part of the transcriptional regulation of the pri-miRNA synthesis that will impact the level of miRNA. These levels.

MicroRNAs have been implicated in neurodegenerative diseases in several ways and can be classified accordingly (reviewed in; Bushati and Cohen, 2007; Eacker et al., 2009; Gascon and Gao, 2012; Kaur et al., 2012). First, it has been shown in several organisms and in various neuronal populations that disruption of the miRNA pathway through Dicer depletion impacts neuronal differentiation and survival (Schafer et al., 2007; Cuellar et al., 2008). Similarly, targeted depletion of Dicer in astrocytes, oligodendrocytes, and Schwann cells leads to neurodegeneration (Shin et al., 2009; Pereira et al., 2010; Tao et al., 2011), pointing out a potential role of glial miRNAs in neurodegenerative diseases. Interestingly, lack of Atxn2, the protein involved in SCA2 disease which interacts with Ago1, impairs the repressive activity of several miRNAs (McCann et al., 2011). However, it is not known whether this dysfunction is physiologically relevant to the SCA2 pathology.

Second, several miRNAs (referred to below as class I neurodegenerative disease-associated miRNAs; NDAmiR) have been shown to target some disease-related proteins and modulate their cellular concentration. For instance, in AD, several miRNAs are able to modulate Aβ peptide production through APP or BACE1 targeting, or repress genes implicated in the phosphorylation state of the Tau protein (reviewed in; Delay et al., 2012). Similarly, several miRNAs may target α-synuclein, a protein linked to PD, while Ataxin-1, the protein implicated in SCA1 disease, is regulated by at least 4 miRNAs (Gascon and Gao, 2012; and references therein). However these studies have been conducted in vitro and it is not currently known whether these regulations are physiologically important in the course of these diseases.

Finally, recent data suggest that miRNA dysregulation may represent an important part of pathological mechanisms involved in neurodegenerative diseases. Dysregulated miRNAs (referred to below as class II NDAmiR) have several origins. Two proteins mutated in familial cases of amyotrophic lateral sclerosis (ALS) or FTLD, the RNA-binding proteins TAR DNA-binding protein-43 (TDP-43) and fused in sarcoma (FUS), have been identified in Microprocessor complexes (Gregory et al., 2004; Kawahara and Mieda-Sato, 2012). Furthermore, TDP-43 also interacts with the RISC complex and is required for the correct expression of a subset of miRNAs in cell cultures (Kawahara and Mieda-Sato, 2012). Therefore, some disease-related proteins may directly dysregulate the expression of some miRNAs (class IIa) through their biogenesis pathway. In contrast to these direct evidences, aberrant expression of miRNAs (class IIb) have been found in a variety of animal models of neurodegenerative diseases and in post-mortem brain samples of AD, PD, and Huntington disease (HD) patients (reviewed in; Lau and de Strooper, 2010; Gascon and Gao, 2012). In only a few cases potential dysregulation mechanisms could be proposed. For instance, in the case of HD, inhibition of the REST co-repressor by the pathological Htt protein likely results in over-expression of at least four neuronal miRNAs (Johnson et al., 2008; Packer et al., 2008). However, several caveats may complicate the interpretation of these data. First, technical issues, such as the stability of miRNAs during the analysis of brains from patients may have led to false positive detection (Sethi and Lukiw, 2009). Then, most studies focused primarily on neuron dysfunctions, and the relative contribution of neurons and glial cells in miRNA dysregulation in vivo was not addressed. However, glial inflammatory responses are observed in many of these diseases and could be responsible for a significant part of miRNA transcriptome modifications. Finally, analyses were usually performed at advanced stages of the diseases where neuronal loss is frequently observed. The observed differences in miRNA concentration may therefore arise from differences in tissue composition compared to the control samples. Alternatively, they may represent unspecific events consecutive to secondary processes occurring in neurodegeneration such as protein homeostasis perturbations or generation of oxidative stress. A critical issue is thus to decipher whether miRNA dysregulation can be observed at the beginning of the pathological process and, subsequently, play a significant role in the evolution of the disease.

In this paper we addressed this issue in Drosophila models related to seven different neurodegenerative diseases (PD, 3 FTLD, 3 dominant ataxias). These models were previously shown to recapitulate many features of human diseases and are amenable to subsequent genetic analysis of miRNAs of interest. We used genetic tools to express pathological proteins specifically in neurons and performed a miRNA profiling by deep sequencing. We found no evidence for a statistically significant difference in
miRNA expression in this early stage of the pathological process. Thus our data suggest that transcriptional deregulation of miRNAs is unlikely to play a significant role in the initial stages of neurodegenerative diseases.

**MATERIALS AND METHODS**

**DROSOPHILA STRAINS AND HUSBANDRY**

For SCA models, the following lines were used: UAS-Atxn1-82Q and UAS-Atxn1-30Q (Fernandez-Funez et al., 2000), UAS-Atxn3-70Q and UAS-Atxn3-19Q, UAS-Atxn7-102Q and UAS-Atxn7-10Q (Latouche et al., 2007). The Atxn3 lines were generated by cloning of the full length Atxn3 coding region described in (Mueller et al., 2009) inside a pAttB-UAS vector followed by insertion at the Att40 landing site by standard ways. For FTLD diseases the following transgenic Drosophila strains were used in this study: UAS-TauV337M (Wittmann et al., 2001); UAS-TDP-43 (Miguel et al., 2011); and UAS-FUS (Miguel et al., 2012). Drosophila strains were raised on standard cornmeal-yeast agar medium. Fly cultures and crosses were carried out at 25°C.

Males from these strains were crossed with elav-GAL4-GeneSwitch (ElavGal4DR) females (Osterwalder et al., 2001). Depending on the protein of interest, more than 500 males or females (0–2 days old) of the progeny were collected (clusters of 25–30) into food tubes containing standard cornmeal-yeast agar medium. After 7 days, the flies were transferred to new tubes containing instant Drosophila media (Carolina Biological Supply, Burlington, NC, USA) or corn yeast medium (SCas experiments) with or without RU486 (Mifepristone, Betapharma-Shanghai Co., Ltd., China) at a final concentration of 1% ethanol and 200 µg/ml RU486. Two days later, the flies were transferred to new tubes containing fresh media for one more day. After these 3 days of RU486 induction, flies were quickly frozen in liquid nitrogen and then stores at −80°C.

For the PD experiments, the following Drosophila strains were used: Canton S, w1118, elav-GAL4, UAS-α-synuclein, and UAS-α-synuclein-A30P (Feany and Bender, 2000). For α-synuclein expression in neurons, elav-GALA virgins were crossed to UAS-α-synuclein or UAS-α-synuclein-A30P males, or to w1118 for controls. 7 to 10-day-old non-virgin females of the F1 progeny were collected (300–350 flies per genotype) and kept at −80°C until RNA extraction.

Paraparquet treatment was performed on 7 to 10-day-old Canton S adult females by dietary ingestion. Fifty flies were incubated at 25°C in a 8.5 cm diameter Petri dish containing two layers of Whatman paper soaked with 20 mM paraquat (methyl viologen, Sigma-Aldrich, St Louis, MO, USA) diluted in 2% (wt/ vol) sucrose or sucrose only for controls. Fourteen similar Petri dishes were independently treated for each condition. After 24 h, around 300 surviving flies were collected and frozen at −80°C.

**TOTAL RNA ISOLATION**

For each head sample, 300 adult fly were frozen in liquid nitrogen and the heads were recovered by sieving. For each body sample used in control experiment, 50 flies were frozen in liquid nitrogen. These frozen samples were directly transferred into a Lysing Matrix D tube containing Lysing Matrix beads ( Qiogen) and 1 ml of qiazol (Qiagen) and grinded with a FastPrep Homogenizer (MP Biomedicals). The homogenate was incubated at room temperature for 5 min and then centrifuged at 12,000 g for 10 min at 4°C to remove cellular debris. The supernatant was transferred to a fresh tube, and 200 µl of chloroform were added per ml of Qiazol. After vortex agitation for 30 s, samples were incubated at room temperature for 3 min and then centrifuged at 16,000 g for 15 min at 4°C. The aqueous phase was transferred to a fresh tube, and RNA was precipitated by adding 1 volume of isopropanol. Samples were incubated for 1 h at −20°C and then centrifuged at 12,000 g for 30 min at 4°C. The RNA pellet was washed by adding 600 µl of cold 80% ethanol and centrifuged at 16,000 g for 10 min at 4°C. The ethanol was then discarded and the pellet air dried for 10 min.

The RNA pellet was dissolved in 20 µl of RNase-free water and 250 µl of acid phenol-chloroform-IAA 125:24:1 (pH 4.5; Ambion) were added. After vortex agitation for 30 s, samples were centrifuged at 16,000 g for 10 min at 4°C. The aqueous phase was transferred to a fresh tube, and 250 µl of chloroform were added. After vortex agitation for 15 s, samples were centrifuged at 16,000 g for 10 min at 4°C. The aqueous phase was transferred to a fresh tube, and 1/10 volume of NaAc (3M, pH 5.0) and 4 volumes of cold 100% ethanol were added. Samples were then incubated overnight at −20°C for RNAs precipitation and centrifuged at 16,000 g for 30 min at 4°C. The RNA pellet was washed with 600 µl of cold 80% ethanol and centrifuged at 16,000 g for 10 min at 4°C. After a second wash step and centrifugation, the RNA pellet was air dried for 10 min and in 50 µl of RNA-free water. Before being further processed, the concentration of RNA samples was measured by spectrophotometry and their quality was checked with an Agilent 2100 Bioanalyzer (Agilent Technologies, Palo Alto, USA).

**DEEP SEQUENCING AND DATA ANALYSIS**

Small RNAs from fly head RNAs were cloned using the using the TruSeq (TM) SBS v5 Kit and sequenced using an Illumina HiSeq 2000 at Fasteri (http://www.fasteri.com/). Sequence reads in fastq format were trimmed from the adapter sequence 5′-CTTGGACCATCACTCAT-3′ and reads with more than 18 nt were matched to the Drosophila melanogaster genome release 5.43 using Bowtie and allowing 0 or 1 mismatch (−v 1 option). Matched reads were then re-matched against (1) the miRBase r18 miRNA stem-loop sequences. Reads matching these sequences with 0 or 1 mismatch were retained for subsequent analysis whereas unmatched reads were re-matched to (2) other non-coding RNA sequences (tRNAs, rRNAs, and miscellaneous ncRNAs). Reads matching these sequences with 0 or 1 mismatch were retained for subsequent analysis whereas unmatched reads were re-matched to (2) other non-coding RNA sequences (tRNAs, rRNAs, and miscellaneous ncRNAs). Reads matching these sequences with 0 or 1 mismatch were retained for subsequent analysis whereas unmatched reads were re-matched to (3) transposon element sequences. This procedure was further iteratively applied to (4) introns, (5) mRNAs, and (6) intergenic sequences to produce the annotations in Table 1.

Using the miRNA_bowtie_profler python script (available upon request), we parsed the bowtie output files to count and map the miRNA reads to the miRNA stem-loop sequences. To assign read counts to either the 5p or 3p miRNAs, each miRNA stem-loop sequence was iteratively split between −20 and +20 nucleotides relative to the middle of the miRNA stem-loop sequence. For each split position, the numbers of reads mapping entirely to the upstream and downstream substrings were computed and stored, whereas reads mapping across the split position were discarded.
Table 1 | miRNAs implicated in neurodegenerative diseases belonging to conserved miRNA families with *Drosophila* members.

| Identified miR | Family_ID | Family_name | dme-miR | Disease | Reference | Variation |
|---------------|-----------|-------------|---------|---------|-----------|-----------|
| hsa-let-7b    | MIPF0000002 | let-7       | dme-let-7 | AD      | Wang et al. (2011) | Down     |
| hsa-let-7c    | MIPF0000002 | let-7       | dme-let-7 | AD      | Wang et al. (2011) | Down     |
| hsa-let-7e    | MIPF0000002 | let-7       | dme-let-7 | AD      | Wang et al. (2011) | Up       |
| hsa-let-7g    | MIPF0000002 | let-7       | dme-let-7 | AD      | Schonrock et al. (2010) | Down     |
| hsa-let-7h    | MIPF0000002 | let-7       | dme-let-7 | AD      | Wang et al. (2011) | Down     |
| hsa-let-7i    | MIPF0000002 | let-7       | dme-let-7 | AD      | Schonrock et al. (2010) | Down     |
| hsa-let-7j    | MIPF0000002 | let-7       | dme-let-7 | AD      | Wang et al. (2011) | Down     |
| hsa-miR-98    | MIPF0000002 | let-7       | dme-let-7 | AD      | Wang et al. (2011) | Down     |
| mmu-let-7b    | MIPF0000002 | let-7       | dme-let-7 | AD      | Wang et al. (2009) | Up       |
| mmu-let-7d    | MIPF0000002 | let-7       | dme-let-7 | AD      | Wang et al. (2009) | Up       |
| mmu-let-7e    | MIPF0000002 | let-7       | dme-let-7 | AD      | Wang et al. (2009) | Up       |
| mmu-miR-98    | MIPF0000002 | let-7       | dme-let-7 | AD      | Wang et al. (2011) | Down     |
| mmu-miR-98    | MIPF0000002 | let-7       | dme-let-7 | AD      | Wang et al. (2011) | Down     |
| cel-let-7     | MIPF0000002 | let-7       | dme-let-7 | PD      | Asikainen et al. (2010) | Down     |
| dme-let-7     | MIPF0000002 | let-7       | dme-let-7 | PD      | Gehrke et al. (2010) | NC       |
| hsa-let-7c    | MIPF0000002 | let-7       | dme-let-7 | PolyQ-HD | Martí et al. (2010) | Down     |
| hsa-let-7d    | MIPF0000002 | let-7       | dme-let-7 | PolyQ-HD | Martí et al. (2010) | Down     |
| hsa-let-7e    | MIPF0000002 | let-7       | dme-let-7 | PolyQ-HD | Martí et al. (2010) | Down     |
| hsa-let-7g    | MIPF0000002 | let-7       | dme-let-7 | PolyQ-HD | Martí et al. (2010) | Up       |
| hsa-let-7h    | MIPF0000002 | let-7       | dme-let-7 | PolyQ-HD | Martí et al. (2010) | Up       |
| hsa-let-7i    | MIPF0000002 | let-7       | dme-let-7 | PolyQ-HD | Martí et al. (2010) | Up       |
| hsa-miR-98    | MIPF0000002 | let-7       | dme-let-7 | PolyQ-HD | Martí et al. (2010) | Down     |
| mmu-miR-125a  | MIPF0000017 | mir-125     | dme-mir-1 | AD      | Wang et al. (2009) | Up       |
| hsa-miR-99a   | MIPF0000025 | mir-99      | dme-mir-100 | AD      | Wang et al. (2011) | Down     |
| hsa-miR-99b   | MIPF0000025 | mir-99      | dme-mir-100 | AD      | Wang et al. (2011) | Down     |
| hsa-miR-100   | MIPF0000025 | mir-99      | dme-mir-100 | PolyQ-HD | Martí et al. (2010) | Down     |
| hsa-miR-99a   | MIPF0000025 | mir-99      | dme-mir-100 | PolyQ-HD | Martí et al. (2010) | Up       |
| hsa-miR-99b   | MIPF0000025 | mir-99      | dme-mir-100 | PolyQ-HD | Martí et al. (2010) | Up       |
| mmu-miR-125a  | MIPF0000017 | mir-125     | dme-mir-100 | PolyQ-HD | Martí et al. (2010) | Up       |
| hsa-miR-133a  | MIPF0000029 | mir-133     | dme-mir-133 | PD      | Kim et al. (2007) | Down     |
| hsa-miR-137   | MIPF0000106 | mir-137     | dme-mir-137 | AD      | Gekkeiyange and Chan (2011) | Down     |
| mmu-miR-137   | MIPF0000106 | mir-137     | dme-mir-137 | AD      | Schonrock et al. (2010) | Down     |
| hsa-miR-137   | MIPF0000106 | mir-137     | dme-mir-137 | PolyQ-HD | Martí et al. (2010) | Down     |
| hsa-miR-137   | MIPF0000106 | mir-137     | dme-mir-137 | Tauopathies | Smith et al. (2011) | NC       |
| hsa-miR-184   | MIPF0000059 | mir-184     | dme-mir-184 | AD      | Wang et al. (2011) | Up       |
| hsa-miR-184   | MIPF0000059 | mir-184     | dme-mir-184 | PolyQ-HD | Martí et al. (2010) | Down     |
| hsa-miR-193b  | MIPF0000082 | mir-193     | dme-mir-193 | AD      | Wang et al. (2011) | Down     |
| hsa-miR-193b  | MIPF0000082 | mir-193     | dme-mir-193 | PolyQ-HD | Martí et al. (2010) | Up       |
| hsa-miR-210   | MIPF0000086 | mir-210     | dme-mir-210 | AD      | Hebert et al. (2008) | Down     |
| hsa-miR-210   | MIPF0000086 | mir-210     | dme-mir-210 | PolyQ-HD | Martí et al. (2010) | Up       |
| hsa-miR-29a   | MIPF0000009 | mir-29      | dme-mir-29 | AD      | Gekkeiyange and Chan (2011) | Down     |
| hsa-miR-29a   | MIPF0000009 | mir-29      | dme-mir-29 | AD      | Shioya et al. (2010) | Down     |
| hsa-miR-29a   | MIPF0000009 | mir-29      | dme-mir-29 | AD      | Wang et al. (2011) | Down     |
| hsa-miR-29a   | MIPF0000009 | mir-29      | dme-mir-29 | AD      | Hebert et al. (2008) | Down     |
| hsa-miR-29a   | MIPF0000009 | mir-29      | dme-mir-29 | AD      | Wang et al. (2011) | Down     |
| mmu-miR-29a   | MIPF0000009 | mir-29      | dme-mir-29 | AD      | Wang et al. (2009) | Down     |
| mmu-miR-29a   | MIPF0000009 | mir-29      | dme-mir-29 | PolyQ-HD | Johnson et al. (2008) | Up       |
| hsa-miR-29c   | MIPF0000009 | mir-29      | dme-mir-29 | PolyQ-HD | Martí et al. (2010) | Down     |
| hsa-miR-29c   | MIPF0000009 | mir-29      | dme-mir-29 | PolyQ-HD | Martí et al. (2010) | Up       |
| mmu-miR-29c   | MIPF0000009 | mir-29      | dme-mir-29 | PolyQ-HD | Johnson et al. (2008) | Down     |
| mmu-miR-29c   | MIPF0000009 | mir-29      | dme-mir-29 | PolyQ-HD | Lee et al. (2008) | Down     |

(Continued)
Then, the split position for which the sum of the upstream and downstream reads was the nearest of the total number of reads mapped to the miRNA stem-loop sequence was retained, and the upstream and downstream read counts were assigned to the 5p and 3p miRNAs, respectively. Using this algorithm, miRNA5p and miRNA3p read counts were unambiguously assigned, independently of miRBase annotations for miRNA and miRNA* species. Note that in the case of non-canonical miRNAs with reads tilted across the stem-loop precursor, the procedure leads to arbitrarily assign read counts to miRNA5p and miRNA3p species which may not be biologically relevant; however, these counts still reflect the expression level of the miRNA stem-loop precursor.

Expression profiling of mature miRNAs was performed using the hit tables generated as described above and the DEseq R package (Anders and Huber, 2010). The recently improved version (1.7.6) was used, with the default options (notably sharing Mode = “maximum” in the estimate Dispersions function).

WESTERN BLOTTING
Fifty adult fly heads were dissected and homogenized in 100 μl RIPA buffer [50 mM Tris-HCl, pH 8, 150 mM NaCl, 20 mM EDTA, 1% Nonidet-P40 (v/v), 50 mM natrium fluoride, 20 mM N-ethylmaleimide, and a cocktail of protease inhibitors from Sigma-Aldrich, St. Louis, MO, USA]. Samples were placed under agitation at 4°C for 1 h and then centrifuged at 11,300 for 20 min at 4°C to remove cellular debris. Protein concentrations in RIPA fraction were measured using the DC Protein Assay Kit (Bio-Rad Laboratories, Hercules, CA, USA). Protein samples were loaded in SDS-PAGE sample buffer (240 mM Tris-HCl, pH 6.8, 6% SDS, 30% glycerol, 0.06% bromophenol blue) and resolved by a 10% SDS-PAGE. Proteins were transferred to nitrocellulose membranes (Hybond C-Extra; Amersham Biosciences, Arlington Heights, IL, USA). The following antibodies were used in this study: rabbit polyclonal anti-TARDBP/TDP-43 (1:5,000; Proteintech Group, Inc., Chicago, IL, USA) and rat monoclonal anti-elav (1:100, Developmental Studies Hybridoma Bank, Iowa City, IA, USA). Membranes were incubated with peroxidase-labeled anti-rat or anti-rabbit antibodies (1:10,000) from Jackson Immunoresearch Laboratories (WestGrove, PA, USA), and signals were detected with chemiluminescence reagents (GE Healthcare, Saclay, France). Signals were acquired with a GBOX (Syngene, Cambridge, UK) monitored by the Gene Snap software.

REAL-TIME QUANTITATIVE RT–PCR
For each genotype, 1 μg of total RNA were first treated with Deoxyribonuclease I Amplification Grade (Sigma-Aldrich) and then reverse-transcribed into cDNA, using the First Strand cDNA Synthesis Kit (Amersham Biosciences). PCR reactions were performed in a final volume of 20 μl, using the SsoFast EvaGreen Supermix (Bio-Rad, Hercules, CA, USA) with primers at a final concentration of 300 nM (primer sequences available upon request). PCR amplifications were performed on a CFX96 Real-Time System (Bio-Rad) using the following cycling steps: enzyme activation at 98°C for 2 min; denaturation and annealing/extension respectively at 98°C for 10 s and 60°C for 15 s for 40 cycles. The comparative –ΔΔCt method was then used to determine quantitative values for gene expression levels in each sample using 14.3.3ε and Cyp1 as normalizer genes.

RESULTS
GENERATION OF miRNA PROFILES AT EARLY DISEASE STAGES IN DROSOPHILA MODELS
Among the miRNAs that have been proposed to be involved in neurodegenerative diseases in mammals, 30 of them belongs to a conserved miRNA family that has at least one member in Drosophila (Table 1). Surprisingly, we noticed in many cases opposite directions of transcriptional changes inside a given family and a given pathology. This points out the need of additional
studies to uncover the functional significance of these observations, and, notably, to investigate whether miRNA dysregulation can be observed at the first stages of the diseases. Therefore our major aim was to focus on class II NDAmiR in *Drosophila* models of human neurodegenerative diseases that have been well characterized previously and amenable to early stage study. Thus we used dominant models of ataxias (SCA1, SCA3, SCA7) and FTLD (TDP-43, FUS, TAU) where pathological or control proteins can be targeted to neurons in a temporally controlled manner with the RU486 inducible ElavGal4 line (see below for complete genotype description). Importantly, since its first introduction in 2007 by one of us to modelize successfully SCA7 pathology (Lautouche et al., 2007), the elavGS system has been used by several labs to study *Drosophila* neurodegenerative disease models. This includes a model for Aβ induced pathology (Sofola et al., 2010; Rogers et al., 2012), models for polyQ diseases (Spinobulbar muscular atrophy (SBMA; Pandey et al., 2007), and SCA3 (Martin-Lannère et al., 2006), model for Parkinson disease (Kanao et al., 2010) as well as the two FTD models used in this study (FUS and TBP43; Lanson et al., 2011; Miguel et al., 2011, 2012). Therefore, it is now widely accepted that inducible elavGS models are adequate to express disease proteins in adult CNS with pathological consequences that mimic the disease. Flies were induced when 7 day-old, by incorporation of RU486 into their food, and RNA extraction was performed on 10 day-old fly heads. As expected from previous characterization of the GeneSwitch system (Osterwalder et al., 2001), proteins are readily detected 24 h after induction (Figure 1A). Thus, with this strategy, we are able to detect early transcriptome changes occurring during the first 3 days of the pathological process.

In addition to these dominant models, we used a model of sporadic PD where flies were treated during 2 days with the neurotoxic compound paracetamol before RNA extraction on fly heads. We completed this study with another model of PD linked to α-synuclein overexpression. In all these cases the age of the flies selected for RNA extraction was 7 days. Therefore they were analyzed separately from the previous batch of samples.

Following RNA extraction and quality control, generation, and sequencing of small RNA libraries were performed on Illumina Hi-Seq. A total of 266 million reads were generated for the 36 samples of this study and were matched to different mutually exclusive categories (miRNAs, tRNAs, ncRNAs, miscRNAs, transposons, Introns, transcripts, and intergenic sequences). A detailed description for each sample is given in Table S1 in Supplementary Material. As a whole, as expected, the miRNAs class is the most abundant (61% of the total; Figure 2). With these selected reads, normalization between samples and subsequent statistical analysis were performed with Deseq (Anders and Huber, 2010), a state of the art software that models the null distribution of the count data with negative binomial distribution and evolved variance. After normalization, we expected the miRNA counts to be highly correlated between samples corresponding to uninduced conditions (RU0) where the pathological proteins are not induced. This was indeed the case as illustrated in Figure 3 for samples issued from SCAs experiment. Therefore we could gain in statistical power by implementing, in the Deseq analysis, an additional set of reference data composed of independent samples corresponding to all the RU0 and other control conditions. This improved the accuracy of variance calculation and thus provides reduced p-values in the analysis. It also take into account the natural variation of miRNA expression in non-pathological flies of different genotypes, which
should be distinguished to pathology related variations. However it should be emphasized that this procedure only improves the estimation of variation between samples of the same biological conditions and that, in all cases, comparisons and differential expression analysis are performed between flies of similar genotypes (induced or not induced) to eliminate genetic background variations. Results presented below have been obtained with this optimized method, although standard analysis (using one to one condition comparison) provides similar conclusions.

To validate our method of analysis we took advantage of the differences of miRNA expression observed in the different body parts. We performed deep-seq analysis on whole body of age matched flies, combined this data with our head control samples and used our pipeline to identify differentially expressed genes in the head. The raw and normalized counts of the miRNAs species are provided in Table S2 Supplementary Material. With our data, we identified 106 statistically significantly ($p < 0.01$) differentially expressed miRNAs, shared between 33 head enriched miRNAs (with ratios $0.08 < \text{WholeBody/Head} < 0.58$) and 73 head depleted miRNAs (with ratios $1.66 < \text{WholeBody/Head} < \infty$). Since similar datasets have been generated in two independent studies (Chung et al., 2008; Berezikov et al., 2011; accession numbers GSM286601, GSM286602, GSM322543, GSM399107) for the modENCODE project, we could compare our WholeBody/Head ratios with these two datasets. We observed a striking correlation between these three independent experiments with 96 out of our 106 differentially expressed miRNAs (91%) being confirmed by the modENCODE data (Figure 4 and Table S2 Supplementary Material). This suggests that our procedure may distinguish differentially expressed miRNAs with high reliability.

The full lists of raw and normalized counts of the 480 Drosophila miRNAs species are provided in Table S3 Supplementary Material for the different conditions corresponding to our neurodegenerative models.

**miRNA PROFILING IN SCAs MODELS**

Transgenic lines used for SCA1 and SCA7 models (UAS-Atxn1-15Q, UAS-Atxn1-82Q, UAS-Atxn7-10Q, UAS-Atxn7-102Q) have been described and characterized earlier (Fernandez-Funez et al., 2000; Latouche et al., 2007). For SCA3 models we generated two new full length Atxn3 transgenic lines derived from constructs described in (Mueller et al., 2009), UAS-Atxn3-15Q and
UAS-Atxn3-70Q. We checked that, similarly to expanded truncated form of Atxn3, expression of the pathological form in adult neurons of elavGal4GS+/+; UAS-Atxn3-70Q flies reduced their lifespan (Figure 1B). These flies present also a progressive decline in climbing performance with a climbing index of 50% of control flies at 23 days and 14% at 30 days. In the same way, expression of the pathological form of ATXN1 in adult neurons of elavGal4GS+/+; UAS-Atxn1-82Q flies reduced their lifespan (Figure 1C).

Importantl, all these SCAs related proteins have been implicated in transcription regulation. Atxn1 and Atxn7 are present in transcription complexes (Helmlinger et al., 2006; Lam et al., 2006) and Atxn3 binds to chromatin and may regulate gene expression by interacting with histone acetylases (Evert et al., 2006). Therefore these proteins are good candidates for a direct regulation of miRNA expression. We profiled miRNAs in two independent samples of total RNA extracted for heads of flies expressing the expanded Atxn proteins and 1 sample for uninduced control flies or flies expressing the normal allele, and performed multiple comparisons of expression with the Deseq software in standard mode. miRNAs presenting fold change greater than 1.5 between expanded protein expressing flies (RU200) and control flies (RU0) are given in Table S3 Supplementary Material. We noticed that many of these selected miRNAs present low expression values or, in some cases, high variability of expression between replicated samples or between the set of control samples. Consequently, in any case, we found no statistically significant difference ($p < 0.01$) in miRNA expression. This suggests that toxicity in the SCAs model in Drosophila is not related to misexpression of miRNAs mediated by the expanded Atxn proteins in the early stages of the disease. However, when we looked more closely to the miRNAs from Table 1 corresponding to conserved miRNA families, we noticed a trend to overexpression of mir-33 and mir-92a in all ataxia models (Table 2), although the statistical significance is below threshold in independent analysis. Closer analysis of these miRNAs at different time points coupled with functional analysis are under progress.

Recently a study in HD models identified 21 nt small CAG repeats RNAs (sCAG) as potential mediators of expanded Htt toxicity (Bañez-Coronel et al., 2012). Thus, in addition from miRNAs profiling, we searched for such species in our in vivo polyQ disease models by mapping all the sequences obtained in one model against the transgene used in this model. In all SCA diseases models we were unable to identify an increase in sCAG (Table 3). Indeed, only two perfect match reads of 18 and 21 nucleotides are detected in the ATXN7-102Q sample, while three and two imperfect match reads are detected in the ATXN1-82Q and ATXN3-70Q samples respectively. Thus, HD may present a specific toxicity mechanism compared to SCAs diseases, although alternative hypothesis discussed in the last section may explain our result.

**miRNA PROFILING IN FTLD MODELS**

Most cases of FTLD are characterized by the abnormal accumulation of either the microtubule-associated protein Tau, the transactive response DNA-binding protein-43 (TDP-43) or the FUS protein. TDP-43 proteins have been shown to facilitate the post-transcriptional processing of a subset of miRNAs not only in the nucleus but also in the cytoplasm (Kawahara and Mieda-Sato, 2012). This sequential facilitation was achieved both
Table 2 | Fold changes observed after induction of the pathological proteins or treatments for miRNAs implicated in neurodegenerative diseases belonging to conserved miRNA families with Drosophila members.

| dme-miR         | elavGS.M.200_ vs_elavGS.M.0 | elavGS.F.200_ vs_elavGS.F.0 | ATXN1.82Q.200_ vs_ATXN1.82Q.0 | ATXN3.70Q.200_ vs_ATXN3.70Q.0 | ATXN7.102Q.200_ vs_ATXN7.102Q.0 | FUS.200_ vs_FUS.0 | TDP43.WT.200_ vs_TDP43.WT.0 | tau.V337F.200_ vs_tau.V337F.0 | par.10_vs_par.0 | syn.A30P_ vs_elav | syn.WT_ vs_elav |
|-----------------|-----------------------------|-----------------------------|-------------------------------|-------------------------------|-------------------------------|-----------------|-----------------------------|-----------------------------|----------------|-----------------|-----------------|
| dme-lent-7_5p   | 0.96                        | 0.94                        | 1.14                          | 1.03                          | 1.15                          | 0.77            | 0.76                        | 0.95                        | 0.78           | 0.75            | 0.84            |
| dme-mir-1_3p    | 0.34                        | 1.20                        | 0.99                          | 0.59                          | 0.76                          | 0.63            | 0.69                        | 0.70                        | 2.52           | 0.50            | 1.01            |
| dme-mir-100_5p  | 1.23                        | 1.02                        | 1.50                          | 1.61                          | 1.44                          | 1.23            | 1.18                        | 1.20                        | 1.40           | 1.10            | 0.80            |
| dme-mir-125_5p  | 0.49                        | 0.90                        | 0.85                          | 0.98                          | 1.31                          | 1.10            | 0.88                        | 0.96                        | 0.98           | 0.68            | 0.52            |
| dme-mir-133_3p  | 1.50                        | 0.92                        | 1.02                          | 1.16                          | 1.31                          | 0.75            | 0.72                        | 0.81                        | 0.91           | 0.96            | 0.77            |
| dme-mir-137_3p  | 1.28                        | 0.93                        | 1.07                          | 1.07                          | 0.93                          | 1.32            | 1.02                        | 1.01                        | 0.67           | 1.29            | 0.83            |
| dme-mir-184_3p  | 0.40                        | 1.13                        | 0.83                          | 0.77                          | 0.70                          | 0.75            | 0.57                        | 0.87                        | 1.45           | 1.36            | 0.97            |
| dme-mir-193_5p  | 0.73                        | 1.09                        | 0.74                          | 0.86                          | 0.86                          | 0.96            | 0.90                        | 0.94                        | 1.47           | 1.12            | 0.79            |
| dme-mir-210_3p  | 0.59                        | 0.96                        | 0.79                          | 0.81                          | 0.75                          | 0.87            | 0.69                        | 0.85                        | 0.98           | 1.22            | 0.87            |
| dme-mir-285_3p  | 1.43                        | 0.97                        | 1.19                          | 1.34                          | 1.38                          | 1.68            | 1.34                        | 1.11                        | 0.80           | 1.20            | 0.89            |
| dme-mir-33_5p   | 1.22                        | 1.04                        | 1.89                          | 1.54                          | 1.79                          | 1.45            | 1.09                        | 1.37                        | 0.53           | 1.55            | 0.91            |
| dme-mir-34_5p   | 1.16                        | 0.97                        | 1.62                          | 1.40                          | 1.42                          | 0.84            | 0.96                        | 1.06                        | 0.44           | 1.73            | 1.00            |
| dme-mir-375_3p  | 0.46                        | 0.91                        | 1.32                          | 0.90                          | 0.89                          | 1.16            | 1.28                        | 0.77                        | 1.11           | 1.02            | 0.88            |
| dme-mir-92a_5p  | 0.91                        | 0.74                        | 1.74                          | 2.00                          | 1.90                          | 1.68            | 1.90                        | 1.78                        | 1.89           | 0.93            | 1.19            |
| dme-mir-92b_3p  | 1.63                        | 1.18                        | 1.47                          | 0.90                          | 0.80                          | 1.33            | 1.06                        | 0.92                        | 1.25           | 0.79            | 1.16            |

Variations greater than 1.5 are highlighted. In all cases, after Benjamini–Hochberg corrections for multiple testing, the DeSeq analysis p-value is 1. See Tables S2 and S3 in Supplementary Material for complete data.
Table 3 | No siRNAs like sequences are generated from CAG repeats.

| Sample         | Coordinate polyQ | Orientation | Position | Sequence                  | N mismatch or insertion | Size |
|----------------|------------------|-------------|----------|---------------------------|-------------------------|------|
| READS MAPPING INTO TRANSGENES |                  |             |          |                           |                         |      |
| ATXN1-82Q      | 1236–1482        | +           | 127        | GCATCAGCATCAGCAGCA       | 2                       | 18   |
| ATXN1-82Q      | 1237–1482        | –           | 1324       | AGCAGCAGCAGCAACAG       | 1                       | 17   |
| ATXN1-82Q      | 1238–1482        | +           | 1347       | CAGCAGCAGCAGCAGCA       | 1                       | 17   |
| ATXN3-70Q      | 1374–1584        | +           | 1517       | GCAGCAGCAGCAGCAACAG     | 2                       | 15   |
| ATXN3-70Q      | 1375–1584        | +           | 1561       | AGCAGCAGCAGCAGCAGC      | 2                       | 21   |
| ATXN7-102Q     | 735–1041         | +           | 779        | GCAGCAGCAGCAGCAGCA      | 0                       | 18   |
| ATXN7-102Q     | 735–1041         | –           | 809        | GCAGCAGCAGCAGCAGC       | 0                       | 21   |
| ATXN7-102Q     | 735–1041         | +           | 821        | ACAGCAGCAGCAGCAGCAGC    | 1                       | 18   |
| ATXN7-102Q     | 735–1041         | +           | 952        | AGCAGCAGCAGCAGCAGC      | 1                       | 16   |
| ATXN7-102Q     | 735–1041         | +           | 976        | AGCAGCAGCAGCAGCAGC      | 1                       | 16   |
| ATXN7-102Q     | 735–1041         | +           | 988        | AGCAGCAGCAGCAGCAGC      | 1                       | 16   |
| ATXN7-102Q     | 735–1041         | +           | 1015       | AGCAGCAGCAGCAGCAGC      | 1                       | 16   |
| ATXN7-102Q     | 735–1041         | –           | 1028       | GAGCAGCAGCAGCAGCAGC     | 2                       | 16   |

N total reads
N reads in transgene
N reads in repeat
N reads in repeat-PM
Reads/kb in transgene
Reads/kb in repeat

The small RNA libraries from the three expanded Atxn protein samples were mapped with Bowtie to the sequence of the corresponding transgene, to identify potential sequences generated from the CAG repeats. All the sequence identified as mapping into the repeat region are depicted here. Notice that the sizes of these sequences do not match with the 21 nt size expected for an siRNA and that most of them present some mismatches, which casts some doubt on their origin. In addition, as shown in the bottom Tab, we did not observe an increase of small RNA production in the repeat region, but, in contrast, a decrease compared to the rest of the transgene sequences.

by the direct binding of TDP-43 to the primary and precursor forms of the miRNAs and by a protein–protein interaction between TDP-43 and the nuclear Drosha and cytoplasmic Dicer complexes. FUS proteins have also been involved in the Drosha complex, but the role of these proteins in miRNA processing has not been elucidated so far (Gregory et al., 2004). Therefore TDP-43 and FUS are good candidates for a direct regulation of miRNA expression. Expression of wild-type form of TDP-43 or FUS proteins was achieved using transgenic Drosophila lines (UAS-TDP-43, UAS-FUS) previously described and characterized (Miguel et al., 2011, 2012). miRNA expression profiling was performed in two independent samples of total RNA extracted from heads of flies expressing (RU200) or not (RU0) TDP-43 or FUS proteins. As shown in Table S3 Supplementary Material, similarly to SCAs models, miRNAs presenting fold change greater than 1.5 between induced and uninduced flies presented low expression values and/or high variability of expression between replicated samples or between the set of control samples, leading to none statistically significant difference (p < 0.01) in miRNA expression.

Concerning Tau proteins, it has been shown that suppression of miRNA maturation enhances Tau-mediated cell death in flies, indicating a protective role of miRNA in Tau neurotoxicity (Bilen et al., 2006). Furthermore, genetic ablation of Dicer in mice results in disease-like changes in endogenous Tau phosphorylation and neurodegeneration (Hébert et al., 2010). However there is no direct indication of miRNA dysregulations in flies expressing Tau. Transgenic lines used for FTLD-Tau model (UAS-TauV337M) have been described and characterized previously (Wittmann et al., 2001). In human, the V337M mutation had originally been described in a family (the Seattle family A) presenting an FTLD. Due to the X chromosomal insertion of the transgene, this particular set of experiments was performed using Drosophila females instead of males. A new set of control samples, corresponding to uninduced UAS-TauV337M/+; elavGS/+ samples (RU0); and elavGS/+ samples (RU0 and RU200), was therefore designed. Again, profiling of miRNA expression in two independent samples showed that miRNAs presenting fold change greater than 1.5 between induced and uninduced flies presented low expression values and/or high variability of expression between replicated samples or between the set of control samples, leading to none statistically significant difference (p < 0.01) in miRNA expression. However, like in ataxia models, mir-92a present trend to overexpression in all FTD models...
We analyzed potential miRNA misregulation in two conditions that mimic Parkinson’s disease in flies. First, we treated the flies with paraquat, a toxicant suspected to be a factor of neurodegeneration in PD (Tanner et al., 2011) that is frequently used in animals to model PD (Cannon and Greenamyre, 2010). Paraquat produces free radicals in cells, which leads to dopamine neuron dysfunction and degeneration in Drosophila (Chaudhuri et al., 2007). Flies were treated with 20 mM paraquat for one-day, a dose that we found induces death of about half of the flies. Second, we used a transgenic model originally described by (Feany and Bender, 2000), in which the PD-implicated human protein α-synuclein or its more pathogenic mutant form α-synuclein-A30P were expressed in all Drosophila neurons starting from early stages of development. In this α-synuclein model, pathological features that include locomotor impairments and dopamine neuron loss only arise after 3 weeks of adult life (Feany and Bender, 2000). We performed our study on 7 to 10-day-old flies to detect potential early effects of α-synuclein neuronal accumulation on miRNA transcription.

As shown in Table S3 Supplementary Material we did not identify any statistically significant change in all the conditions analyzed. For instance, in the paraquat experiment, although mean fold changes between paraquat treated flies and control flies greater than two were observed rather frequently, they usually resulted from fluctuations in one of the four samples not confirmed in the other replicate. Compared to SCAs and FTLD studies where 100% flies are alive at the time of RNA extraction, higher variations in read counts may have resulted from greater heterogeneity in flies submitted to paraquat treatment that were recovered at the 50% survival time.

**DISCUSSION**

In this study, we investigated in several Drosophila models of neurodegenerative diseases whether miRNA misexpression may be observed after expression of toxic proteins (SCAs, FTLD, genetic PD) or toxic treatment (sporadic PD). In contrast to other profiling studies in model organisms or in humans, we measured miRNA expression at an early stage of the pathological process (3 days after toxic protein induction or treatment), in an attempt to uncover early transcriptional dysregulations linked to the diseases. However, no statistical significant variations in miRNA expression were observed in any of the cases.

Many studies previously reported differences in some miRNA expression in worm and mice models of AD, HD, PD or in post-mortem patient brain samples. In the latter case, a potential drawback of miRNA profiling is the limited stability and relatively short half-life (1–3.5h) of some miRNAs (especially those with AT- TA content). Indeed, brain samples of post-mortem intervals (PMI) greater than 4h and as high as 27h hours (Martí et al., 2010) have been used in some studies, which may lead to overstated conclusions. Noticeably, miRNAs found differentially expressed in some of these studies (Martí et al., 2010; Wang et al., 2011) present higher percentages of AT-TA content (11%) than the complete miRNA collection (9%). Therefore, as already suggested by Sethi and Lukiw (2009), much care should be brought to sample collections and only experiments using samples with PMI < 2h should be considered for future analysis and comparisons with animal models.

This potential problem of miRNA stability does not usually exist for analysis of samples from animal models (including our study) where fast freezing of tissues is performed. Thus, in addition to the reliable human data from low PMI samples, the reports of differential expression of miRNAs in worm and mice models for AD, HD, and PD are at odds with our findings, since they suggest that miRNA dysregulation is a common feature of neurodegenerative diseases. However, a significant difference with our study focused on the earliest stages of the pathological processes, is that miRNA profiling has been usually performed in aged animals where the pathological features are already present.

Since most of the diseases analyzed in our study with Drosophila models (SCAs, FTLDs) have not been submitted to similar miRNA profiling in mouse models, we cannot exclude the lack of miRNA dysregulation in these pathologies. Alternatively, the lack of significant miRNA dysregulation in our study may reflect the progressivity of the diseases. In this view the earliest stages following expression of a pathological protein would not be associated to changes in miRNA transcriptome while, at subsequent stages, some miRNAs would be dysregulated. Secondary events such as inflammation processes could play an important role in these latter steps. In agreement to this scheme miRNA-146a, a cytokine responsive miRNA, is induced in late stages of AD mouse models but not in younger animals (Li et al., 2011). Importantly, in contrast to miRNA, mRNA misregulation may be observed at early stages in at least some of our models. We and others have already documented early transcriptome changes as early as 12 h of paraquat treatment (Zou et al., 2000; Girardot et al., 2004).

In addition, after completion of our study, one of us used the same RNA samples to perform mRNA deep- seq analysis on the 3 FTP models. Between 69 and 327 mRNAs were misregulated on these models, Although the description of this work is outside the scope of this paper, we confirmed here the induction of 5 chaperones by qRT-PCR analysis in the TauV337M model (Table 4). This shows that mRNA misregulation can occur 72h after the pathological protein induction in at least four models used in this study.

In terms of potential therapeutic strategies it is important to elucidate whether miRNAs are early or late players in the neurodegenerative pathological processes. Therefore subsequent profiling experiments at different time points in the various animal models available are required to address this issue. In the case of Drosophila models particular attention should be brought to the two members of conserved mir family, mir-33, and mir-92a, that show trend toward overexpression in some models, albeit not statistically significant at this early time point. Notice, however, that, in these kinetic studies, conducted at the latter stages of the diseases, the issue of changes in tissue...
Table 4 | Examples of deep sequencing analysis of mRNA species and validation by RT-qPCR.

| Gene id | Count A | Count A’ | Count B | Count B’ | Mean A | Mean B | Deep-seq fold change | padj | RT-qPCR fold change↑ | RT-qPCR fold change↑ |
|---------|---------|----------|---------|----------|--------|--------|----------------------|------|---------------------|---------------------|
| DnaJ-1  | 1923    | 1697     | 2211    | 2891     | 1799   | 2530   | 1.41                 | 2.4E-05 | 1.33                | 1.37                |
| Hsp83   | 14887   | 13143    | 17140   | 22448    | 13939  | 19636  | 1.41                 | 1.9E-05 | 1.22                | 1.26                |
| Hsp68   | 483     | 430      | 497     | 486      | 452    | 718    | 1.59                 | 3.0E-08 | 1.64                | 1.70                |
| Hsp70Bc | 110     | 95       | 164     | 393      | 101    | 277    | 2.73                 | 1.7E-31 | 1.32                | 1.37                |
| Hsp70Aa | 342     | 247      | 663     | 1301     | 292    | 966    | 3.31                 | 9.1E-61 | 1.50                | 1.57                |

Table S3 | Number of read counts without normalization (“raw data” sheet) or normalized (“norm data” sheet) for all the miRNA species identified in the samples of this study. miRBase r18 was used for read assignment as indicated in the Section “Material and Methods.”

Table S4 | Results of statistical analysis with DeSeq. For each of the comparisons analyzed for SCAs, FTLD, and PD models, the miRNAs with fold changes greater than two or lower than 0.5 are provided with the probability value for significant change calculated before (p-value) or after (padj) adjustment for multiple testing using the Benjamini-Hochberg (BH) method. On each line the minimum (Min), maximum (Max), medium (Mean), and standard deviation (SD) of the control samples used in DeSeq variance analysis are given, in addition to the absolute values of the samples.
REFERENCES

Anders, S., and Huber, W. (2010). Differential expression analysis for sequence count data. Genome Biol. 11, R106.

Asikainen, S., Rudgalvyte, M., Heikki-Cannon, J. R., and Greenamyre, J. T. (2007). MicroRNA expression profiling of Caenorhabditis elegans Parkinson’s disease models. J. Mol. Neurosci. 41, 210–218.

Bak, M., Silahtaroglu, A., Møller, M., Christensen, M., Rath, M. F., Skryabin, B., et al. (2008). MicroRNA expression in the adult mouse central nervous system. RNA 14, 432–444.

Barza-Coronel, M., Porta, S., Kagerbauer, B., Mateu-Huertas, E., Pantano, L., Ferrer, I., et al. (2012). A pathogenic mechanism in Huntington’s disease involves small CAG-repetitive RNAs with neurotoxic activity. PLoS Genet. 8, e1002481. doi:10.1371/journal.pgen.1002481

Bergerok, E., Bobine, N., Samsonova, A., Westholm, J. O., Naqui, A.,Hung, J. H., et al. (2011). Deep annotation of Drosophila melanogaster microRNAs yields insights into their processing, modification, and emergence. Genome Res. 21, 203–215.

Bilen, J., Liu, N., Burnett, B. G., Pittman, R. N., and Bonini, N. M. (2006). MicroRNA pathways modulate polyglutamine-induced neurodegeneration. Mol. Cell 24, 157–163.

Brookmeyer, R., Evans, D. A., Hebert, S. S. (2012). National estimates of the prevalence of Alzheimer’s disease in the United States. Alzheimer Disease 7, 61–73.

Buratti, E., De Conti, L., Stuani, C., Romano, M., Baralle, M., and Baralle, E. (2010). Nuclear factor TDP-43 can affect selected microRNA levels. FEBS J. 277, 2268–2281.

Bushati, N., and Cohen, S. M. (2007). A Drosophila model of Parkinson’s disease. Neurobiol. Dis. 29, 235–240.

Chung, D. W., Rudnicki, D. D., Yu, L., and Margolis, R. L. (2011). A natural antisense transcript at the Huntington’s disease repeat locus regulates HTT expression. Hum. Mol. Genet. 20, 3467–3477.

Chung, W.-J., Okamura, K., Martin, R., and Lai, E. C. (2008). Endogenous RNA interference provides a somatic defense against Drosophila transposons. Curr. Biol. 18, 795–802.

Czellar, T. L., Davis, T. H., Nelson, P. T., Loeb, G. H., Barfe, D. B., Ullian, E., et al. (2008). Dicer loss in striatal neurons produces behavioral and neuroanatomical phenotypes in the absence of neurodegeneration. Proc. Natl. Acad. Sci. U.S.A. 105, 5614–5619.

Delay, C., Mandemakers, W., and Hebert, S. S. (2012). MicroRNAs in Alzheimer’s disease. Neurobiol. Dis. 46, 285–290.

Ecker, S. M., Dawson, T. M., and Dawson, V. L. (2009). Understanding microRNAs in neurodegeneration. Nat. Rev. Neurosci. 10, 837–841.

Evert, B. O., Araujo, J., Vieira-Saecker, A., de Vos, R. A., Harendra, S., Klockgether, T., et al. (2006). Ataxin-3 represses transcription via chromatin binding, interaction with histone deacetylase 3, and histone deacetylation. J. Neurosci. 26, 1174–1186.

Feany, M. B., and Cohen, S. M. (2000). A Drosophila model of Huntington’s disease. Nature 404, 394–398.

Fernandez-Funez, P., Eberlin, A., Bowman, A. B., Garnamuller, A., et al. (2006). Glutamine-expanded ataxin-3 alters TTP/CSTAGA recruitment and chromatin structure leading to photoreceptor dysfunction. PLoS Biol. 4, e67. doi:10.1371/journal.pbio.0040067

Hébert, S. S., Porceddu, S., Langa, K. M., Heeringa, S. G., Plassman, B. L., et al. (2011). The diverse functions of BACE1/beta-secretase expression. Neurobiol. Dis. 40, 1147–1155.

Hébert, S. S., Papadopoulou, A. S., Smith, P. A., Galas, M. C., Planell, S., Silahtaroglu, A. N., et al. (2010). Genetic ablation of Dicer in adult forebrain neurons results in abnormal tau hyperphosphorylation and neurodegeneration. Hum. Mol. Genet. 19, 5959–5969.

Helminger, D., Hardy, S., Abou-Sleymane, G., Eberlin, A., Bowman, A. B., Garnamuller, A., et al. (2006). Glutamine-expanded ataxin-3 alters TTP/CSTAGA recruitment and chromatin structure leading to photoreceptor dysfunction. PLoS Biol. 4, e67. doi:10.1371/journal.pbio.0040067

Luo, S., Yu, Z., Xue, C., Zhan, R., and Wang, L. C. (2007). MicroRNA functions. Nat. Rev. Neurosci. 8, 469–481.

Luo, S., Yu, Z., Zhan, R., and Wang, L. C. (2007). MicroRNA functions. Nat. Rev. Neurosci. 8, 469–481.

Menssen, A., Breitling, R., Maltz, A., King, H., Smith, R., Kim, J. H., Taylor, J. P., et al. (2011). A Drosophila model of FUS-related neurodegeneration reveals genetic interaction between FUS and TDP-43. Hum. Mol. Genet. 20, 2510–2523.

Romano, M., Baralle, M., and Baralle, E. (2004). The diverse functions of microRNA-mediated translational repression. Nature 408, 101–106.

Gascon, E., and Gao, F. B. (2012). A Caenorhabditis elegans Parkinson’s disease model provides a reversible adult phenotype for identifying modifier genes. J. Neurosci. 27, 2483–2492.

Luo, S., Yu, Z., Xue, C., Zhan, R., and Wang, L. C. (2007). MicroRNA functions. Nat. Rev. Neurosci. 8, 469–481.

Luo, S., Yu, Z., Xue, C., Zhan, R., and Wang, L. C. (2007). MicroRNA functions. Nat. Rev. Neurosci. 8, 469–481.

Menssen, A., Breitling, R., Maltz, A., King, H., Smith, R., Kim, J. H., Taylor, J. P., et al. (2011). A Drosophila model of FUS-related neurodegeneration reveals genetic interaction between FUS and TDP-43. Hum. Mol. Genet. 20, 2510–2523.

Luo, S., Yu, Z., Xue, C., Zhan, R., and Wang, L. C. (2007). MicroRNA functions. Nat. Rev. Neurosci. 8, 469–481.

Luo, S., Yu, Z., Xue, C., Zhan, R., and Wang, L. C. (2007). MicroRNA functions. Nat. Rev. Neurosci. 8, 469–481.
Newman, M. A., and Hammond, S. M. (2010). Emerging paradigms of reg-ulated microRNA processing. Genes Dev. 24, 1086–1092.

Osterwalder, T., Yoon, K. S., White, B. H., and Keshishian, H. (2001). A conditional tissue-specific transgene expression system using inducible GAL4. Proc. Natl. Acad. Sci. U.S.A. 98, 12596–12601.

Packer, A. N., Xing, Y., Harper, S. Q., Jones, L., and Davidson, B. L. (2008). The bifunctional microRNA mir-9/mir-9a regulates REST and CoREST and is downregulated in Huntington's disease. J. Neurosci. 28, 14341–14346.

Pandey, U. B., Nie, Z., Batlevi, Y., McCray, B. A., Ritsos, G. P., Nedel-sky, N. B., et al. (2007). HDAC6 rescues neurodegeneration and pro-vides an essential link between autophagy and the UPS. Nature 447, 859–863.

Pereira, J. A., Baumann, R., Larkin, A., Lee, P., et al. (2012). Accumu-lation of insoluble forms of FUS protein correlates with toxicity in neurodegenerative models. Neuron 72, 6763–6775.

Rogers, I., Kerr, F., Martinez, P., Hardy, I., Lovestone, S., and Par-tridge, L. (2012). Ageing increases vulnerability to αβ42 toxicity in Drosophila. PLoS One 7, e40569. doi:10.1371/journal.pone.0040569

Schonrock, N., Ke, Y. D., Humphreys, D., Staufnhiel, M., Ittner, L. M., Preiss, T., et al. (2010). Neuronal microRNA deregulation in response to Alzheimer's disease amyloid-beta. PLoS One 5, e11070. doi:10.1371/journal.pone.0011070

Scherer, A., O'Carroll, D., Tan, C. L., Millman, D., Sugimori, M., Li-nas, R., et al. (2007). Cerebellar neurodegeneration in the absence of microRNAs. J. Exp. Med. 204, 1553–1558.

Sethi, P., and Lukin, W. J. (2009). MicroRNA abundance and stability in human brain: specific alterations in Alzheimer's disease temporal lobe neocortex. Neurosci. Lett. 459, 100–104.

Shin, D., Shin, J. Y., McManus, M. T., Ptacek, L. J., and Fu, Y. H. (2009). Dicer ablation in oligodendrocytes provokes neuronal impairment in mice. Am. Neuro. 66, 843–857.

Shiroya, M., Ohayashi, S., Tabunoki, H., Arima, K., Saito, Y., Ishida, T., et al. (2010). Aberrant microRNA expression in the brains of neu-rodegenerative diseases: miR-29a decreased in Alzheimer disease brains targets neuroneavigator 3. Neuropathol. Appl. Neurobiol. 36, 320–330.

Siomi, H., and Siomi, M. C. (2010). Posttranscriptional regulation of microRNA biogenesis in animals. Mol. Cell 38, 323–332.

Smith, P., Al Hashimi, A., Girard, J., Delay, C., and Hebert, S. S. (2011). In vivo regulation of amyloid precursor protein neuronal splicing by microRNAs. J. Neurochem. 116, 240–247.

Sofola, O., Kerr, F., Rogers, L., Killick, R., Augustin, H., Gandy, C., et al. (2010). Inhibition of GSK-3 ameliorates Abeta pathology in an adult-onset Drosophila model of Alzheimer’s disease. PLoS Genet. 6, e1001087. doi:10.1371/journal.pgen.1001087

Tanner, C. M., Kamel, F., Ross, G. W., Hoppin, J. A., Goldman, S. M., Korell, M., et al. (2011). Rotenone, paraquat, and Parkinson’s disease. Environ. Health Perspect. 119, 866–872.

Tao, J., Wu, H., Lin, Q., Wei, W., Lu, X., Cattle, J. P., et al. (2011). Dele-tion of astroglial Dicer causes non-cell-autonomous neuronal dysfunc-tion and degeneration. J. Neurosci. 31, 8396–8419.

Wang, L. C., Chen, K. Y., Pan, H., Wu, C., Chen, P. H., Liao, Y., et al. (2011). Muscleblind participates in RNA toxicity of expanded CAG and CUG repeats in Caenorhabditis elegans. Cell. Mol. Life Sci. 68, 1255–1267.

Wang, X., Liu, P., Zhu, H., Xu, Y., Ma, C., Dai, X., et al. (2009). miR-34a, a microRNA up-regulated in a double transgenic mouse model of Alzheimer’s disease, inhibits bcl2 translation. Brain. Res. Bull. 80, 268–273.

Wittmann, C. W., Wszolek, M. F., Shlumlin, J. M., Salvaterra, P. M., Lewis, J., Huston, M., et al. (2001). Tauopathy in Drosophila: neurodegeneration without neu- rofibrillary tangles. Science 293, 711–714.

Yankner, B. A., Lu, T., and Loerch, P. (2008). The aging brain. Annu. Rev. Pathol. 3, 41–66.

Zou, S., Meadows, S., Sharp, L., Jan, L. Y., and Jan, Y. N. (2000). Genome-wide study of aging and oxidative stress response in Drosophila melanogaster. Proc. Natl. Acad. Sci. U.S.A. 97, 13726–13731.

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any com-mercial or financial relationships that could be construed as a potential con-flict of interest.